Three therapeutic tendencies for secondary prevention of myocardial infarction and possible role of Chinese traditional patent medicine: Viewpoint of evidence-based medicine

Journal of Evidence-Based Medicine

Volumn 2, Issue 2, 2009, Pages 84-91

  Shang, Hongcai ^a,b   Chen, Jing ^c   Zhang, Junhua ^a   Xiang, Yaozu ^a   Cao, Hongbo ^a   Ren, Ming ^a   Wang, Hui ^a   Xu, Hongjuan ^a   Li, Jing ^a   Liu, Dan ^a   Hu, Jing ^a   Wu, Chao ^a   Jing, Li ^a   Zhang, Boli ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SICHUAN UNIVERSITY   (China)

^c Tianjin Chest Hospital   (China)

Author keywords

Chinese traditional patent medicine; Evidence based medicine; Myocardial infarction; Secondary prevention; Therapeutic tendency

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHINESE DRUG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGINA PECTORIS; BLEEDING; CHINESE MEDICINE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HEALTH EDUCATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MYOPATHY; PATENT; PATIENT SAFETY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

EVIDENCE-BASED MEDICINE; HUMANS; MEDICINE, CHINESE TRADITIONAL; MYOCARDIAL INFARCTION; SECONDARY PREVENTION;

EID: 77953380365     PISSN: 17565383     EISSN: 17565391     Source Type: Journal    
DOI: 10.1111/j.1756-5391.2009.01004.x     Document Type: Review

References (71)

1. McMurray JJV. Advancement and revolution of treatment for AMI. American Heart Association 2003.
2. Gu DF. Current situation and prospect of cardiovascular disease treatment. Chinese Journal of Preventive Medicine 2003; 37(2): 75.
3. Tao SQ. Prevention and treatment of cardiovascular disease. Science and Technology Review 1994; 11(11): 62.
4. Fernandes AW, Madhavan SS, Amonkar MM. Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population. Clinical Therapeutics 2005; 27(5): 630-45.
5. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Journal of the American Medical Association 1982; 247: 1707-14.
6. Ueshima K, Fukami K, Hiramori K, Hosoda S, Kishida H, Kato K, et al. Is angiotensin-converting enzyme inhibitor useful in a Japanese population for secondary prevention after acute myocardial infarction? A final report of the Japanese Acute Myocardial Infarction Prospective (JAMP) study. American Heart Journal 2004; 148(2): 292-9.
7. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
8. CCS-I. Effects of captopril on mortality and complication after acute myocardial infarction (protocol). Chinese Journal of Hypertension 1994; 2(1): 4-8.
9. Jiang SL, Zhang Y, JI XP, Wang XR, Song ZF, Wang R. Effect of Chinese guidelines issued in 2001 on in-hospital management and prognosis of patients with acute myocardial infarction. Chinese Journal of Cardiology 2005; 33(9): 779-82.
10. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. New England Journal of Medicine 1993; 328: 673-9.
11. Hasnain D, Philip HE, John LC. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. British Medical Journal 2004; 7(5): 287-91.
12. Goldberg R, Glatfelter K, Burbank-Schmidt E, Lessard D, Gore J. Trends in community mortality due to coronary heart disease. American Heart Journal 2006; 151: 501-7.
13. Tan Z, Huang DJ. Research current situation of aspirin resistant. Chinese Journal of Cardiology 2004; 32(6): 551-4.
14. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 2005; 294(19): 2437-45.
15. Simon SR, Black HR, Moser M, Berland WE. Cough ACE inhibitors. Archives of Internal Medicine 1992; 152(8): 1698-700.
16. Os I, Bartland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992; 339(8789): 372.
17. Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche JM, et al. Impact of combined secondary prevention therapy after myocardial infarction: Data from a nationwide French registry. American Heart Journal 2005; 150(6): 1147-53.
18. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. European Heart Journal 2006; 27(14): 1651-6.
19. Tang YP, Liu JC. Progress of treatment of acute myocardial infarction by traditional Chinese medicine. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease 2005; 3(12): 3901.
20. Ni J, Chen XY, Zheng J. Comment on literatures of clinical randomized controlled trials of traditional Chinese medicine for acute myocardial infarction. Journal of Guangzhou University of Traditional Chinese Medicine 2003; 20(1): 82-5.
21. Zhang BL, Gao XM, Shang HC, Zhao YJ, Wang YY. Study on pharmaceutical matters and functional mechanisms of complex Prescriptions of Radix Salvial Milti Orrhizal. World Science Technology-Modernization of Traditional Chinese Medicine 2003; 5(5): 14-17.
22. Bensoussan A, Myers S. Towards a safer choice: The practice of traditional Chinese medicine in Australia. Sydney, Australia: Department of Human Services, NSW Dept Health, and QLD Dept Health. University of Western Sydney, 1996.
23. North Dakota Academy of Science Chinese herbal medicine and the cardiovascular system: looking through the mirror. In: North Dakota Academy of Science (editors). Proceedings of the North Dakota Academy of Science Symposium; 2001; 55: 30-33.
24. Chen KJ, Shi DZ, Xu H, Lü SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chinese Medical Journal 2006; 119(1): 6-13.
25. Tang YP, Liu Y, Liang P. Clinical study on preventing and treating left ventricle remodeling after acute myocardial infarction with integrative Chinese and western medicine. Chinese Journal of Integrative Medicine 2004; 10(1): 25-8.
26. Zhang JG, Gao DS, Yang N, Liu LX, He H, Dong HX, et al. Effect of astragalus injection on left ventricular remodeling in aged patients with acute early-stage myocardial infarction. Chinese Journal of Integrative Medicine 2003; 9(2): 104-7.
27. Zuo YT. Shengmai injection for angina pectoris attacks of old myocardial infarction patients. Practical Clinical Journal of Integrated Chinese and Western Medicine 2006; 6(1): 59.
28. Zhou HJ, Huang J. Shengmai injection and thrombolysis for acute myocardium infarction. Chinese Archives of Traditional Chinese Medicine 2005; 23(4): 749-50.
29. Liu ZM, Wang YS, Yang LL, Zhao SJ. Protective effects of Shengmai injection on ischemic myocardium in patients with acute myocardial infarction. Journal of Jilin University (Medicine Edition) 2005; 31(2): 311-3.
30. Miao YM, Chen FL, Ma MH. Shengmai injection for reperfusion injury of acute myocardium infarction after thrombolysis. Center for Maternal Fetal Medicine 2005; 18(4): 363-4.
31. Li YH, Wu SP, Zhao CJ, et al. Shengmai injection for aging non-ST elevation acute myocardium infarction. Chinese Medicine of Factories and Mines 2004; 2(6): 4-7.
32. Zhang YC, Zhao MH, Lv BJ, et al. Shengmai injection for acute myocardium infarction along with left cardiac dysfunction. Academic Journal of Shanghai Second Medical University 2004; 24(8): 692.
33. Chen YS, He ZH, Yu H. Shengmai injection for acute myocardium infarction along with cardiac shock. China New Medicine 2004; 3(4): 114-5.
34. Zhao HB, Guo AM, Wang NZ. Shengmai injection for acute myocardium infarction along with arrhythmia. Journal of Emergency in Traditional Chinese Medicine 2004; 13(11): 745-6.
35. Jia ZM, Ma LL, Li QF. Shengmai injection for reperfusion injury of myocardium. Traditional Chinese Medicine Research 2003; 16(6): 61-2.
36. Li YX, Xiao GW. Effects of Shengmai injection on myocardial infarction without initial ST elevation in senile patient. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease 2006; 4(1): 17-8.
37. Geng QX, Zhu XL, Zhang XH, Zhu M, Tang YS, Lv XX, et al. Effect of combined therapy of Shenmai and compound Danshen injection for myocardial reperfusion injury after percutaneous coronary intervention in patients with acute myocardial infarction. Practical Clinical Journal of Integrated Chinese and Western Medicine 2004; 24(6): 496-9.
38. Ding XZ. Shenmai injection for acute myocardium infarction along with cardiac dysfunction. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease 2003; 1(2): 115-6.
39. Yan J, Yang JY. Acanthopanax with Shengmai injection for myocardium infarction. Chinese Journal of Guangming Traditional Chinese Medicine 2004; 19(1): 60-1.
40. Yu ZQ, Su WQ, Li SY, Tang YF, Ma RM. Effect of Naoxintong capsule on the exercise tolerance and endothelial function in the patients with acute myocardial infarction. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease 2005; 3(12): 1037-9.
41. Li HT. Astragalus mongholicus injection for acute myocardium infarction. Chinese Preventive Medicine Journal 2005; 32(7): 49.
42. Wang SS, He YH, Wang LL. Linaoxin capsule for old myocardium infarction. Jilin Traditional Chinese Medicine 2004; 24(12): 62.
43. Yuan ZM, Geng RA, Zhao WY. Composite salvia miltiorrhiza injection along with thrombolysis for acute myocardial infarction. Shanxi Traditional Chinese Medicine 2003; 24(2): 107-8.
44. Qin QT, Wang XM. Prevention and treatment effect of composite salvia miltiorrhiza injection on acute myocardial infarction patients with reperfusion injury by thrombolytic cure. Practical Clinical Journal of Integrated Chinese and Western Medicine 2003; 10(4): 242-4.
45. Li J, Jiang T. The effect of compound Danshen pill to acute myocardial infarction left ventricle reconstruction. Tianjin Pharmacy 2003; 15(1): 36-8.
46. He FT, Li LJ, Bai JY, et al. Integration of traditional Chinese and Western medicine for acute myocardial infarction. Journal of Emergency in Traditional Chinese Medicine 2004; 13(7): 421-2.
47. Jia LW, Du YY. Wenxinkeli for asymptomatic myocardial ischemia and ventricular premature contraction after myocardial infarction. Journal of Traditional Chinese Medicine 2006; 47(2): 124.
48. Liang Y, Chen C, Xu GF, Chen JS, Zhang LY, Ye HP, et al. Effect of wenxinkeli on reperfusion arrhythmias in direct percutaneous coronary intervention of acute myocardial infarction. Journal of Clinical Cardiology (China) 2005; 21(10): 601-2.
49. Su YS, Li XZ. Wenxinkeli along with Aspartate Potassium Magnesium for arrhythmia after myocardial infarction. Journal of Emergency in Traditional Chinese Medicine 2004; 13(12): 802-3.
50. Cai WB, Wu WH, Diao J. Wenxinkeli for heart rate variation after myocardial infarction. Chinese Journal of Coal Industry Medicine 2004; 7(11): 1071.
51. Feng X, Zheng XT, Wang J. Wenxinkeli for arrhythmia after myocardial infarction. Huaxia Medicine 2004; 5: 25-6.
52. Huang W, Yan YL. The treatment of Wenxinkeli on the tachycardia arrythmia after acute myocardium infarction. Hainan Medicine 2004; 15(5): 1-4.
53. Xu HG, Zhang L, Yan JL. Wenxinkeli for reperfusion arrhythmias after acute myocardial infarction of the elders. Clinical Focus 2003; 18(3): 156.
54. Shi Q. Tongxinluo capsule for left cardiac dysfunction after acute myocardial infarction. Shandong Medicine 2006; 46(10): 60-1.
55. Li ZX, Li ZH, Chen YH. Influence of Tongxinluo capsule on infarct area and cardiac function in acute myocardial infraction patients. Hebei Medicine 2006; 12(8): 741-3.
56. Zhang JW, Yang DC. Protective effects of Tongxinluo on myocardium after reperfusion in patients with acute myocardium infarction. Medicine Industry Information 2006; 3(21): 8-10.
57. YouSJ, YangYJ,ChenKJ, WuYJ,JingZC, ZhangJ,etal. The protective effects of Tongxinluo on myocardium and microvasculature after reperfusion in acute myocardial infarction. Chinese Journal of Cardiology Medicine 2005; 33(5): 433-7.
58. You SJ, Chen KJ, Yang YJ, Gao RL, Wu YJ, Zhang J, et al. Clinical study on spontaneous improvement after blood flow reconstruction interfered by Tongxinluo capsule in patients with early stage acute myocardial infarction. Practical Clinical Journal of Integrated Chinese and Western Medicine 2005; 25(7): 604-7.
59. Zhang DE. Tongxinluo capsule for heart rate variation after myocardial infarction. Central Plains Medical Journal 2005; 32(20): 25-6.
60. Xie T, Luo W, Liang J. Tongxinluo capsule for reperfusion injury after myocardial infarction. China Modern Medicine 2005; 4(2): 45-6.
61. You SJ, Yang YJ, Chen KJ, Wu YJ, Jing ZC, Zhang J, et al. Efficacy and safety of Tongxirauo capsule in patients with acute myocardial infarction after reperfusion. Chinese Journal of Difficult and Complicated Cases 2004; 3(4): 193-6.
62. Fan Y, Zhang YN, Jiang LH, Yu CY, Zhu XY, Yu WG. Effects of Tongxinluo capsule on patients with post-infarction angina pectoris. Journal of Harbin Medical University 2003; 37(5): 439-40.
63. Qiu J. China plans to modernize traditional medicine. Nature 2007; 446(7136): 590-1.
64. Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. Journal of the American College of Cardiology 2002; 39(7): 1083-95.
65. Wu TX, Li YP, Bian ZX, Li TQ, Li J, Dagenais S, et al. Consolidated standards for reporting trials of traditional Chinese medicine (CONSORT for TCM). Chinese Journal of Evidence-based Medicine 2007; 7(8): 601-5.
66. Editorial. Is GSK guilty of fraud? Lancet 2004; 363: 1919.
67. Altman DG, Simera I, Hoey J, Moher D, Schulz KF. EQUATOR: reporting guidelines for health research. Lancet 2008; 371(9619): 1149-50.
68. Moher D, Simera I, Schulz KF, Hoey J, Altman DG. Helping editors, peer reviewers and authors improve the clarity, completeness and transparency of reporting health research. BMC Medicine 2008; 6: 13.
69. Wu TX, Li YP, Bian ZX, Chen KJ, Zhang BL, Shang HC, et al. Practicing good publication practice to improve the transparence of clinical trials. Chinese Journal of Evidence-based Medicine 2007; 7(8): 551-4.
70. Shang HC, Dai GH, Zhang JH, et al. Myocardial infarction secondary prevention study. American Journal of Geriatric Cardiology 2006; 3(2): 116-9.
71. Nahin RL, Straus SE. Research into complementary and alternative medicine: problems and potential. British Medical Journal 2001; 322: 161-4.